Anika Sharma
United Therapeutics acquires Miromatrix for bioengineered organ research
United Therapeutics is set to enhance its arsenal of organ manufacturing technologies with the acquisition of Miromatrix Medical, a developer ...
Abingworth raises $356M to back late-stage biopharma ventures
Abingworth, a renowned international life sciences investment group, has successfully closed a new fund, raising an impressive $356 million. This ...
Almirall relaunches psoriasis miniseries to highlight mental health impact
Almirall is seizing the occasion of World Psoriasis Day to underscore the profound impact of this skin condition on mental ...
PBMs Launch Media Blitz Advocating for Cost-Cutting Reforms and Policy Changes
A coalition of pharmacy benefit managers (PBMs) has taken an innovative step to counter the negative image that has dogged ...
Pfizer Announces New Jersey Site Closure and Layoffs in $3.5B Cost-Cutting Initiative
The financial ramifications of Pfizer’s revenue decline due to the COVID-19 pandemic are now revealing their human toll as the ...
GSK’s Jemperli Shows Promise in Endometrial Cancer Trial – FDA Label Expansion on the Horizon
GSK has achieved a significant milestone with its PD-1 inhibitor, Jemperli, in the treatment of endometrial cancer, potentially opening the ...
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead
Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...
Klick Health Welcomes Ellen Cappellino, Former AstraZeneca and Vertex Executive, as Value, Access, and Reimbursement Director
Klick Health, a prominent healthcare marketing agency, has recently appointed Ellen Cappellino, a distinguished figure in the pharmaceutical industry, to ...
ElevateBio slashes 13% of workforce despite huge fundraising
Despite having a substantial $401 million in funding, ElevateBio is streamlining its operations, resulting in job cuts that will impact ...
UCBās Swiss plant gets Form 483 from FDA over quality and records
UCB Farchim, a subsidiary of Belgian pharmaceutical company UCB, is facing regulatory scrutiny from the FDA. The FDA recently issued ...
Bristol Myersā new CEO aims to boost weak new drug launches
Bristol Myers Squibb (BMS) is addressing concerns about its underperforming new products, expressing confidence in their future success. The company’s ...
Eisai, Biogenās Leqembi reduces amyloid in Alzheimerās, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Takeda writes off $770M after failures of Alofisel and Exkivity
Takeda, the Japanese pharmaceutical company, is grappling with significant impairment charges totaling 115.8 billion Japanese yen ($770 million) in its ...
EuroAPI chief Karl Rotthier resigns amid strategic review
In a swift and significant personnel decision, EuroAPI’s board of directors has announced the departure of CEO Karl Rotthier, effective ...
RLS to offer CDMO services for radiopharma at 8 US locations
The biopharmaceutical landscape is witnessing a seismic shift towards radiopharmaceuticals, with major players like Eli Lilly making substantial investments, exemplified ...
Accenture Song acquires ConcentricLife for $245M to boost ad capabilities
Accenture, known for its relentless pursuit of acquisitions, has returned to the deal table once again. The global services company, ...
Merck boosts revenue outlook on COVID-19 pill Lagevrio demand
In a surprising turn of events, Merck’s COVID-19 antiviral pill, Lagevrio, has defied expectations by generating an astounding $640 million ...
3M CEO updates on healthcare spinoff amid revenue decline
In a recent company update, 3M has provided insights into the status of its long-anticipated healthcare business spinout, indicating that ...
Alnylam, Biogen show gene-silencing data for Alzheimerās therapies
This week, Alnylam and Biogen took a significant step toward redefining the landscape of Alzheimer’s disease treatment by revealing promising ...
Pfizer, BioNTech ready flu-COVID combo vaccine for phase 3 trial
In an exciting race reminiscent of their previous encounters, Pfizer and BioNTech have once again taken on their recurring competitor, ...
BioSenic seeks to survive cash crunch and enter phase 3 for GvHD drug
BioSenic, the Belgian biotech born from the merger of Bone Therapeutics and Medsenic last year, is devising a survival plan ...
Medtronic, Edwardsā TAVR devices match surgery in long-term studies
At the Transcatheter Cardiovascular Therapeutics conference in San Francisco, both Medtronic and Edwards Lifesciences unveiled the latest results from ongoing ...
Roche, Biogen end patent dispute over Actemra biosimilar
Roche has swiftly resolved a patent infringement lawsuit it initiated against Biogen in July. The legal dispute centered around Biogen’s ...
GSKās RSV vaccine poised for label expansion after trial success
Five months after GSK made history by securing FDA approval for its respiratory syncytial virus (RSV) vaccine, Arexvy, the company ...
Abbottās Amulet, Bostonās Watchman equal in heart occluder trial
The study, presented as a late-breaking feature at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, assessed the safety and ...
Araclonās Alzheimerās vaccine shows promise in phase 2 trial
Araclon Biotech, a subsidiary of Grifols, has unveiled promising early evidence regarding the effectiveness of its Alzheimer’s disease vaccine. In ...
Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph
At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...
AstraZenecaās nasal flu vaccine nears FDA approval
AstraZeneca’s FluMist, a nasal spray flu vaccine with a two-decade history, is poised to potentially become available for self-administration as ...
RSV outbreak causes shortage of Sanofi, AZās Beyfortus
Shortly after Sanofi and AstraZeneca secured a significant FDA approval for their respiratory syncytial virus (RSV) antibody, Beyfortus, the highly ...
